Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especial…
Author: The Medical News
Phase III data for Suvorexant, an investigational insomnia medicine, announced
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed…
UC Irvine receives CIRM grant to advance stem cell-based treatments for AD, retinitis pigmentosa
Efforts to begin human clinical trials using stem cells to treat Alzheimer’s disease and retinitis pigmentosa received a $37.3 million boost from the California Institute for Regenerative Medicine during its most recent round of funding on Sept. 5.
Omeros files OMS824 IND with FDA to initiate clinical trials for cognitive disorders
Omeros Corporation today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate clinical trials evaluating OMS824, the Company’s lead compound from its phosphodiesterase 10…
DuraSite 2 ophthalmic drug delivery system from InSite Vision
InSite Vision Incorporated today introduced DuraSite 2, its next-generation enhanced drug delivery system which provides a broad platform for developing superior ophthalmic therapeutics.
Scientists identify three new genes associated with Primary Angle Closure Glaucoma
Singapore scientists have identified three new genes associated with Primary Angle Closure Glaucoma (PACG), a leading cause of blindness in Chinese people. PACG affects 15 million people worldwide, 80% of whom live in Asia.
OptiMedica Catalys Precision Laser System for creating corneal incisions receives FDA 510(k) clearance
Global ophthalmic company OptiMedica Corp. has announced U.S. Food and Drug Administration 510(k) market clearance of its Catalys Precision Laser System for creating single-plane and multi-plane arc cuts/incisions in the cornea during cataract surgery.
Useful vision maintained long term after lens-sparing vitrectomy for ROP
Infants treated with lens-sparing vitrectomy for retinopathy of prematurity maintain a level of visual acuity necessary for useful vision into their eighth year of life, study results show.
Tips for parents to help their kids get a smart start to the academic year
The first day of school always requires preparations — notebooks, pens and a new set of clothes. But don’t forget to prepare for your child’s health, says Dr. Joan Bregstein, a physician in the Division of Pediatric Emergency Medicine at NewYork-Presb…
Researchers develop glue mixture that may reduce risks after laser vision correction surgery
Kansas State University researchers have developed a glue mixture that may reduce risks after laser vision correction surgery.
‘ESASO Course Series’ for ophthalmologists
In the new book series ‘ESASO Course Series’, the essentials of the courses of the European School for Advanced Studies in Ophthalmology (ESASO) are made available to interested ophthalmologists, optometrists, technicians and residents all over the world.
Molecular Partners, Allergan to develop and commercialize DARPins against ophthalmic diseases
Allergan, Inc. and Molecular Partners AG today announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the …
Study identifies mode of death of cone photoreceptor cells in animal model of RP
Research conducted at the Angiogenesis Laboratory at Massachusetts Eye and Ear Infirmary, has for the first time, identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigmentosa (RP).
Overcorrection is a risk in pediatric exotropia surgery
One-third of pediatric patients treated surgically for intermittent exotropia have excellent post-treatment alignment, and two-thirds have satisfactory control of the condition after the procedure, show UK study results.
Taro, Sun Pharma enter merger agreement
Sun Pharmaceutical Industries Ltd. and Taro Pharmaceutical Industries Ltd. announced today that they have entered into a merger agreement together with certain affiliates of Sun Pharma.
Genentech receives FDA approval for Lucentis to treat diabetic macular edema
Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes …
Lucentis receives FDA approval for treatment of diabetic macular edema
The U.S. Food and Drug Administration today approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.
Worldwide data reveal gaps in elderly eye care
Worldwide eye examination rates among older adults are very low, despite this age group being recommended to have an eye test at least every 1–2 years, say researchers from Canada.
Plasma exchange is beneficial additive to optic neuritis treatment
The addition of plasma exchange to pulsed intravenous corticosteroid treatment of acute optic neuritis associated with neuromyelitis optica results in improved visual acuity, show study results.
FDA grants 510(k) clearance to VICTUS Femtosecond Laser Platform
Bausch + Lomb, the global eye health company, and Technolas Perfect Vision GmbH, a leading ophthalmology laser company, announced today that the VICTUS Femtosecond Laser Platform received 510(k) clearance from the U.S. Food and Drug Administration.